Entities / Company
Puma Biotechnology.
pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Gone quiet
No new reports in 90+ days-
MarketBeat reported consensus ratings for Puma Biotechnology on June 18, 2026.Some support1 report
-
Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Puma Biotechnology.Some support1 report1 development inside
-
Zacks Investment Research provided stock analysis and recommendations for Puma Biotechnology.Speculative1 report
-
Puma Biotechnology, based in Los Angeles, received FDA approval for NERLYNX cancer treatments and presented findings in New York City.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around Puma Biotechnology this week
News at the entities that move Puma Biotechnology most-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Puma Biotechnology
-
Royal Bank of Canada StructuralRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves Puma Biotechnology
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Puma Biotechnology
-
Los Angeles Shared contextLos Angeles City Council voted to allow noncitizen voting in city elections, supported by Angelica Salas.Moves Puma Biotechnology
-
Thailand Shared contextHeavy rains caused flooding in Bangkok, while a weather system affected both Thailand and Myanmar, with local volunteers involved.Moves Puma Biotechnology
-
FDA Mentioned togetherGeneric medicine services are seeking approval for launch from the FDA.Moves Puma Biotechnology
Connections
The 7 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Puma Biotechnology is subject to formal regulation by the SEC, requiring the filing of transaction details.
-
Douglas Hunt Transactional
Insider Douglas Hunt sold shares of Puma Biotechnology on 2026-07-01.
-
Thailand Shared context
Puma Biotechnology launched its NERLYNX product line into the market of Thailand.
-
MarketBeat Mentioned together
MarketBeat reports on consensus ratings for the company Puma Biotechnology.
-
Royal Bank of Canada Structural
Royal Bank of Canada has increased its stake in the biopharmaceutical company Puma Biotechnology.
-
Los Angeles Shared context
Puma Biotechnology is based in and operates within the context of Los Angeles.
-
FDA Mentioned together
The provided evidence only details FDA drug approvals and does not mention Puma Biotechnology.
History
Events by the month they beganJune 2026
4 events- MarketBeat reported consensus ratings for Puma Biotechnology on June 18, 2026.
- Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Puma Biotechnology.
- Zacks Investment Research provided stock analysis and recommendations for Puma Biotechnology.
- Puma Biotechnology, based in Los Angeles, received FDA approval for NERLYNX cancer treatments and presented findings in New York City.